Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Hospira, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Hospira, Inc. - Product Pipeline Review - 2014', provides an overview of the Hospira, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Hospira, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Hospira, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Hospira, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Hospira, Inc.'s pipeline products Reasons to buy - Evaluate Hospira, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Hospira, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Hospira, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Hospira, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hospira, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Hospira, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Hospira, Inc. Snapshot 5 Hospira, Inc. Overview 5 Key Information 5 Key Facts 5 Hospira, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Hospira, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Hospira, Inc. - Pipeline Products Glance 13 Hospira, Inc. - Late Stage Pipeline Products 13 Filing rejected/Withdrawn Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Hospira, Inc. - Clinical Stage Pipeline Products 15 Phase I Products/Combination Treatment Modalities 15 Hospira, Inc. - Early Stage Pipeline Products 16 Discovery Products/Combination Treatment Modalities 16 Hospira, Inc. - Drug Profiles 17 diclofenac sodium 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 epoetin zeta 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 filgrastim 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 pegfilgrastim 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 rituximab biosimilar 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 bevacizumab biosimilar 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Hospira, Inc. - Pipeline Analysis 25 Hospira, Inc. - Pipeline Products by Target 25 Hospira, Inc. - Pipeline Products by Route of Administration 26 Hospira, Inc. - Pipeline Products by Molecule Type 27 Hospira, Inc. - Pipeline Products by Mechanism of Action 28 Hospira, Inc. - Recent Pipeline Updates 29 Hospira, Inc. - Dormant Projects 30 Hospira, Inc. - Discontinued Pipeline Products 31 Discontinued Pipeline Product Profiles 31 E-21R 31 Hospira, Inc. - Company Statement 32 Hospira, Inc. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Hospira, Inc. - Key Manufacturing Facilities 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Hospira, Inc., Key Information 5 Hospira, Inc., Key Facts 5 Hospira, Inc. - Pipeline by Indication, 2014 8 Hospira, Inc. - Pipeline by Stage of Development, 2014 9 Hospira, Inc. - Monotherapy Products in Pipeline, 2014 10 Hospira, Inc. - Partnered Products in Pipeline, 2014 11 Hospira, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Hospira, Inc. - Filing rejected/Withdrawn, 2014 13 Hospira, Inc. - Phase III, 2014 14 Hospira, Inc. - Phase I, 2014 15 Hospira, Inc. - Discovery, 2014 16 Hospira, Inc. - Pipeline by Target, 2014 25 Hospira, Inc. - Pipeline by Route of Administration, 2014 26 Hospira, Inc. - Pipeline by Molecule Type, 2014 27 Hospira, Inc. - Pipeline Products by Mechanism of Action, 2014 28 Hospira, Inc. - Recent Pipeline Updates, 2014 29 Hospira, Inc. - Dormant Developmental Projects,2014 30 Hospira, Inc. - Discontinued Pipeline Products, 2014 31 Hospira, Inc., Other Locations 34 Hospira, Inc., Subsidiaries 35 Hospira, Inc., Key Manufacturing Facilities 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.